rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapy.

Immunotherapy
Wenliang DongYi Fang

Abstract

Aim: This meta-analysis aimed to evaluate the pharmacokinetics, efficacy, safety and immunogenicity of rHuPH20-facilitated subcutaneous (SC) administration of monoclonal antibody compared with intravenous (IV) administration for patients with cancer. Materials & methods: Outcomes included trough concentrations (Ctrough), overall response rate, adverse events, serious adverse events and antidrug antibody positivity rate. Subgroup analysis was also performed. Results: Five studies involving 1575 participants (788/787) were included. All studies met the non-inferiority criterion in Ctrough. No significant differences were observed in overall response rate (p = 0.12), adverse events (p = 0.05), and severe adverse events (p = 0.73) between SC and IV groups. The SC group also had lower immunogenicity than the IV group. Conclusion: rHuPH20-facilitated subcutaneous administration of monoclonal antibody is highly similar to IV administration in terms of pharmacokinetics, efficacy, and safety, but with lower immunogenicity.

References

Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
Jan 10, 2003·Statistics in Medicine·Ralph B D'AgostinoLisa M Sullivan
Apr 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K TobinaiUNKNOWN IDEC-C2B8 Japan Study Group
Sep 12, 2008·Clinical Pharmacology and Therapeutics·W WangJ P Balthasar
Jul 22, 2009·Journal of Clinical Pharmacology·Diane D WangKourosh Parivar
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old
Jul 17, 2013·The AAPS Journal·Anas M FathallahSathy V Balu-Iyer
May 14, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio SalarGayane Tumyan
Feb 28, 2017·British Journal of Clinical Pharmacology·Samo RozmanBarbara Jezeršek Novaković
Jul 30, 2017·The Oncologist·Jeroen J M A HendrikxJos H Beijnen
Jul 26, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Beate BittnerJohannes Schmidt

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03277105
NCT00930514
NCT01292603
NCT01200758
NCT00950300

Software Mentioned

Stata
Revman
Cochrane

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Nicole L Jarvi, Sathy V Balu-Iyer
Pediatrics
Coburn H AllenINcreased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration Study Collaborative Research Group
© 2021 Meta ULC. All rights reserved